| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/21/2005 | CA2547785A1 Cyclic guanidines, compositions containing such compounds and methods of use |
| 07/21/2005 | CA2546039A1 Novel polymorphs of racemic, dextrorotatory, and levorotatory enantiomers of 1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesylate salts |
| 07/21/2005 | CA2542957A1 Liquid perfluoropolymers and medical applications incorporating same |
| 07/21/2005 | CA2532207A1 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| 07/20/2005 | EP1555267A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES |
| 07/20/2005 | EP1555266A1 Remedies or preventives for urinary frequency or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group |
| 07/20/2005 | EP1555265A1 7-phenyl pyrazolopyridine compounds |
| 07/20/2005 | EP1555032A1 Medicinal composition for treating arteriosclerosis |
| 07/20/2005 | EP1555025A2 Use of dehydroepiandrosterone analogs for the treatment of asthma |
| 07/20/2005 | EP1555024A1 Antibacterial medicinal composition of enhanced oral absorptivity |
| 07/20/2005 | EP1555023A2 Injectable buprenorphine microparticle compositions and their use |
| 07/20/2005 | EP1555022A1 Sustained release compound of acetamidophenol and tramadol |
| 07/20/2005 | EP1555021A1 Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer |
| 07/20/2005 | EP1555020A2 Benzimidazole derivatives as modulators IgE |
| 07/20/2005 | EP1555019A1 Pharmacologic drug combination in vagal-induced asystole |
| 07/20/2005 | EP1555018A1 Remedies for neurodegenerative diseases |
| 07/20/2005 | EP1555008A1 Tooth bleaching composition |
| 07/20/2005 | EP1554936A1 Ketoprofen-supplemented animal feed and use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain |
| 07/20/2005 | EP1554586A2 Screening method |
| 07/20/2005 | EP1554393A2 P27 prevents cellular migration |
| 07/20/2005 | EP1554381A2 Post transcriptional silencing by short interfering rnas |
| 07/20/2005 | EP1554315A1 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| 07/20/2005 | EP1554304A1 Ship 1 modulators |
| 07/20/2005 | EP1554301A2 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
| 07/20/2005 | EP1554299A2 Novel pentose derivatives as anti-hyperglycemic drugs |
| 07/20/2005 | EP1554298A1 Process for the preparation of 9-beta-anomeric nucleoside analogs |
| 07/20/2005 | EP1554290A2 Analogs and prodrugs of buprenorphine |
| 07/20/2005 | EP1554286A1 Fused heterocyclic isoxazoline derivatives and their use as anti-depressants |
| 07/20/2005 | EP1554281A2 Process for preparing certain pyrrolotriazine compounds |
| 07/20/2005 | EP1554275A2 Compounds |
| 07/20/2005 | EP1554272A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| 07/20/2005 | EP1554268A1 Pyrazole inhibitors of the transforming growth factor |
| 07/20/2005 | EP1554265A2 Compounds, compositions and methods |
| 07/20/2005 | EP1554256A1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 07/20/2005 | EP1554254A1 Novel compounds |
| 07/20/2005 | EP1554253A1 Imidazolium cxcr3 inhibitors |
| 07/20/2005 | EP1554245A1 Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| 07/20/2005 | EP1554244A1 1-heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 07/20/2005 | EP1554243A1 Bicyclic benzamide compounds as histamine h3 receptor ligand useful in the treatment of neurological diseases |
| 07/20/2005 | EP1554240A1 Substituted tetralins and indanes and their use |
| 07/20/2005 | EP1554237A1 Methods for synthesis of acyloxyalkyl derivatives of gaba analogs |
| 07/20/2005 | EP1554236A1 Novel bioactive diphenyl ethene compounds and their therapeutic applications |
| 07/20/2005 | EP1554015A1 Treatment of amm |
| 07/20/2005 | EP1553981A1 Bacterial transforming agent |
| 07/20/2005 | EP1553974A1 Pharmaceutical composition comprising carriers for products |
| 07/20/2005 | EP1553973A2 eNOS MUTANTS USEFUL FOR GENE THERAPY |
| 07/20/2005 | EP1553969A1 Use of ghrelin for treating malnutrition in gastrectomised individuals |
| 07/20/2005 | EP1553967A1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne |
| 07/20/2005 | EP1553962A1 Combination chemotherapy with chlorotoxin |
| 07/20/2005 | EP1553960A1 Neuregulin based methods and compositions for treating cardiovascular diseases |
| 07/20/2005 | EP1553959A1 Method for extracting a natural mixture of conjugated equine estrogens that is depleted of non-conjugated lipophilic compounds |
| 07/20/2005 | EP1553958A1 Method of administering bisphosphonates |
| 07/20/2005 | EP1553957A1 Bisphosphonates for the treatment of atherosclerosis and devices comprising them |
| 07/20/2005 | EP1553956A2 Formulation for lipophilic agents |
| 07/20/2005 | EP1553955A2 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 07/20/2005 | EP1553954A2 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 07/20/2005 | EP1553953A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
| 07/20/2005 | EP1553952A1 Use of dihydroimidazolones for the treatment of epilepsy in dogs |
| 07/20/2005 | EP1553951A2 Methods of using and compositions comprising a jnk inhibitor for the treatment, prevention, management and/or modification of pain |
| 07/20/2005 | EP1553950A1 Therapeutic treatment |
| 07/20/2005 | EP1553948A1 Combination of a) n-(5(5-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia |
| 07/20/2005 | EP1553947A2 Quinazolinones and derivatives thereof as factor xa inhibitors |
| 07/20/2005 | EP1553946A2 Enhancement of sleep with t-type calcium channel antagonists |
| 07/20/2005 | EP1553945A2 Nitroxide radioprotector formulations and methods of use |
| 07/20/2005 | EP1553944A1 Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist |
| 07/20/2005 | EP1553943A1 Use of tenatoprazole for the treatment of gastroesophageal reflux |
| 07/20/2005 | EP1553942A1 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 07/20/2005 | EP1553941A1 Lisinopril/lercanidipine combination therapy |
| 07/20/2005 | EP1553940A1 Parenteral formulations containing a rapamycin hydroxyester |
| 07/20/2005 | EP1553939A1 Epothilone derivatives for the treatment of multiple myeloma |
| 07/20/2005 | EP1553938A1 Use of epothilone derivatives for the treatment of hyperparathyroidism |
| 07/20/2005 | EP1553937A2 Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| 07/20/2005 | EP1553936A2 Treatment and rehydration composition which is used to limit the side effects of gastro-enteritis in adults |
| 07/20/2005 | EP1553935A2 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer |
| 07/20/2005 | EP1553934A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 07/20/2005 | EP1553933A1 Medicine comprising a thiourea for use as depigmenting agent or anti-mutagenic and anti-carcinogenic agent |
| 07/20/2005 | EP1553932A2 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 07/20/2005 | EP1553931A1 Compounds, compositions, and methods |
| 07/20/2005 | EP1553929A2 Controlled release preparation |
| 07/20/2005 | EP1553928A1 Oral pharmaceutical compositions of fenofibrate having high bioavailability |
| 07/20/2005 | EP1553927A2 Gel-stabilized nanoparticulate active agent compositions |
| 07/20/2005 | EP1553925A1 Modified release oral dosage form |
| 07/20/2005 | EP1553924A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 07/20/2005 | EP1553923A1 Camptothecin-carboxylate formulations |
| 07/20/2005 | EP1553922A1 Salmeterol superfine formulation |
| 07/20/2005 | EP1553912A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/20/2005 | EP1553909A2 Quick dissolve compositions and tablets based thereon |
| 07/20/2005 | EP1553904A2 Topical patch preparation kit containing a delayed-type hypersensitivity inducer |
| 07/20/2005 | EP1553832A2 Cell separation compositions and methods |
| 07/20/2005 | EP1553831A2 Process for screening fungitoxic compounds |
| 07/20/2005 | EP1472251B1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals |
| 07/20/2005 | EP1429748B1 Solid compositions comprising ramipril |
| 07/20/2005 | EP1401467A4 Alpha-fetoprotein peptides and uses thereof |
| 07/20/2005 | EP1392670B1 Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives |
| 07/20/2005 | EP1385852B1 Compounds and methods for inhibiting mrp1 |
| 07/20/2005 | EP1381606B1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 07/20/2005 | EP1379511B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| 07/20/2005 | EP1345605B1 THERMOFORMed SOLID PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF PERINDOPRIL |
| 07/20/2005 | EP1317309B1 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant |
| 07/20/2005 | EP1303514B1 Process for preparing azacycloalkanoylaminothiazoles |